News coverage about Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Verona Pharma plc – American Depositary Share earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.2953689022409 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Verona Pharma plc (“Verona Pharma” or the “Company”) Reports Operational Update and Financial Results for Full Year Ended December 31, 2017 (finance.yahoo.com)
- Verona Pharma plc – American Depositary Share (VRNA) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
- Verona Pharma plc – American Depositary Share (VRNA) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Verona Pharma plc – American Depositary Share (VRNA) Coverage Initiated at Berenberg Bank (americanbankingnews.com)
Shares of Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) traded up $0.03 during midday trading on Tuesday, reaching $15.03. 1,400 shares of the company were exchanged, compared to its average volume of 4,664. Verona Pharma plc – American Depositary Share has a 1-year low of $10.44 and a 1-year high of $17.50.
TRADEMARK VIOLATION WARNING: “Verona Pharma plc – American Depositary Share (VRNA) Earning Somewhat Positive News Coverage, Analysis Finds” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3225708/verona-pharma-plc-american-depositary-share-vrna-earning-somewhat-positive-news-coverage-analysis-finds.html.
About Verona Pharma plc – American Depositary Share
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company?s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.